Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Clinical Validity
GBA1 (glucocerebrosidase) is definitively implicated in Type I Gaucher disease, an autosomal recessive lysosomal storage disorder characterized by glucocerebrosidase deficiency leading to visceral and bone pathology. Hundreds of unrelated probands across diverse ethnic backgrounds have been reported with biallelic GBA1 variants and consistent clinical presentations over more than three decades, with multiple family segregation studies and concordant functional data supporting a Definitive association.
Genetic Evidence
Type I Gaucher disease follows an autosomal recessive inheritance pattern. Family studies, such as in Portuguese sibships, identified a subclinical N370S/1066+1 G>A case with three other symptomatic siblings segregating the variants ([PMID:8064820]). Across cohorts, more than 500 individuals, including 9 previously unrecognized Ashkenazi Jewish N370S homozygotes identified out of 8 069 screened, manifest clinical features despite presumed asymptomatic status ([PMID:20837833]). Case reports document heteroallelic N370S/L444P, P401L, V375L, and other missense or complex alleles in singletons and multi-family series.
Variant Spectrum
Over 200 unique GBA1 mutations have been described. The common N370S variant (c.1226A>G (p.Asn409Ser)) occurs in >60% of alleles in Ashkenazi Jewish and other populations and retains ~20–30% residual enzyme activity in fibroblasts ([PMID:1877626]). Novel missense alleles such as c.1319C>T (p.Pro440Leu) are associated with severe skeletal phenotypes ([PMID:10340647]). Loss-of-function frameshifts and splice-site variants further diversify the spectrum, and founder mutations exhibit population specificity.
Functional Evidence
Biochemical assays and mutagenesis studies confirm that GBA1 mutations cause enzyme destabilization or active-site disruption. Site-directed replacements at Glu235 and Glu340 abolished catalytic activity, affirming their roles as acid/base catalyst and nucleophile ([PMID:8294487]). Variants such as N370S and G202R are amenable to chemical chaperoning, restoring 2–4-fold activity in patient‐derived cells when treated with iminosugar analogs ([PMID:16298303]).
Therapeutic Modulation
Chemical chaperones like Miglustat (NB-DNJ) increase residual glucocerebrosidase activity in cells expressing mild GBA1 alleles (e.g., N370S) by stabilizing misfolded enzyme, illustrating a rescue strategy beyond enzyme replacement ([PMID:16039881]).
Conclusion
Biallelic pathogenic variants in GBA1 cause Type I Gaucher disease via loss-of-function of lysosomal glucocerebrosidase. Robust genetic and functional concordance supports definitive clinical utility of molecular testing for diagnosis, family screening, and therapeutic decision-making. Key take-home: molecular identification of GBA1 variants directly informs diagnosis, prognosis, and enzyme replacement or chaperone therapy.
Gene–Disease AssociationDefinitiveHundreds of unrelated probands across diverse populations with biallelic GBA1 variants, consistent autosomal recessive segregation, and robust functional concordance Genetic EvidenceStrongBiallelic variants identified in >500 individuals; multiple family segregation studies; variant spectrum with >200 pathogenic alleles Functional EvidenceStrongExtensive biochemical, cell-based, and mutagenesis studies demonstrate loss-of-function and chemical chaperone rescue |